Status:
UNKNOWN
Pharmacokinetic Study on the Combination of Everolimus-Tacrolimus
Lead Sponsor:
Hospital Universitario Ramon y Cajal
Collaborating Sponsors:
Novartis
Astellas Pharma Inc
Conditions:
Kidney Diseases
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to address the pharmacokinetic (PK) profiles of everolimus and tacrolimus in combination in de novo kidney transplant recipients, comparing 1.5 and 3 mg per day of everoli...
Detailed Description
To address the pharmacokinetic profiles of everolimus and tacrolimus in combination in de novo kidney transplant recipients, comparing 1.5 and 3 mg per day of everolimus in fixed doses. For comparison...
Eligibility Criteria
Inclusion
- Kidney transplant recipients aged 18-65 years old with a presumed immediately functioning graft
Exclusion
- Non-functioning kidneys
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
June 1 2007
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00325325
Start Date
January 1 2006
End Date
June 1 2007
Last Update
October 26 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Ramón y Cajal
Madrid, Spain, 28034